Clinical Trial Update: Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating orelabrutinib in combination with BR/G as first-line therapy for untreated marginal zone lymphoma is currently recruiting. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: Marginal Zone Lymphoma | Phase 2 | Status: RECRUITING